Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

o target novel therapies for melanoma."

"I am pleased that the European Association of Dermato-Oncology (EADO) will be the lead international cooperative group for AGENDA," said Dr. Claus Garbe, Professor of Dermatology and Head of the Division of Dermatooncology, Department of Dermatology, University Medical Center, Tubingen, Germany. "The use of LDH to pre-select individuals who are disproportionately likely to benefit represents an important innovation for patient treatment."

"The Genasense/dacarbazine trial represents our highest treatment priority for patients with advanced melanoma," said Dr. Sanjiv Agarwala, Chief of Medical Oncology, St. Luke's Hospital and Health Network, Allentown, PA. "With our center now actively enrolling patients, we look forward to rapidly confirming the exciting results previously obtained in individuals with low- normal LDH."

About Genasense in Advanced Melanoma

Genasense, Genta's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma. Genasense in melanoma has Orphan Drug designations in Australia and the U.S., along with Fast Track designation in the U.S.

In its initial Phase 3 trial, Genta performed the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma. In that trial, 771 patients were randomly assigned to receive chemotherapy with DTIC alone or in combination with Genasense. A scientific article that describes efficacy and safety results from this study can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

In that trial, patients were also prospectively stratified according to blood levels LDH. Further analysi
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... LONDON , October 31, 2014 ... Nanosphere Inc. (NASDAQ: NSPH ), Isis Pharmaceuticals ... (NASDAQ: HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... SNTA). Free research on these five companies can be ... October 30, 2014, the NASDAQ Composite ended at 4,566.14, ...
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... infringe two Australian patents of B. Braun Melsungen AG (B. ... Australia safety IV catheters manufactured by Poly Medicure ... Australia proceeding number VID 463 of ... In the detailed judgment, Multigate was found to have ...
(Date:10/31/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Isis Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights ... a.m. ET / 8:30 a.m. PTWhere: , ... log onto our website listed above. If you are ... of the webcast will be available for a limited ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... increases the risk of certain types of breast cancer ... studies show. One study of more than 3,200 ... risk for estrogen receptor-negative and progesterone receptor-positive breast tumors ... long time for white women, but now we are ... John, a senior research scientist at the Cancer Prevention ...
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2
... Department of Emergency Medicine has received a two-year, $150,000 ... the implementation of electronic health records in a suburban ... work of Michael Ward, MD, an assistant professor at ... year focusing on simulation modeling in operations research, working ...
... , TUESDAY, June 7 (HealthDay News) -- Imaging ... a detrimental effect on the brain, according to a new ... of the drug caused a decrease in the number of ... bodily functions, including concentration, movement coordination, pleasure, pain tolerance, memory ...
... , TUESDAY, June 7 (HealthDay News) -- People ... do relatively few surgeries are at greater risk for serious ... were more common among patients at hospitals with low surgical ... according to the study, published online June 7 in ...
... sounds, smells and events: far too much for us to ... be snagged by something startling, such as a slamming door, ... to us right then, such as locating our child among ... know that people are hard-wired to seek out and pay ...
... (HealthDay News) -- Being in a serious relationship is not ... new research suggests. In fact, a study by researchers ... times more likely to have unprotected sex than casual partners. ... nearly 70 percent of all new HIV/AIDS diagnoses among adolescents ...
... U.S. Department of Agriculture (USDA)-funded studies of mammary gland ... interest may aid breast cancer research. In an early ... C. M. Simmen of the Arkansas Children,s Nutrition Center (ACNC) ... rat mammary gland health were improved in the offspring (pups) ...
Cached Medicine News:Health News:Using simulation to model the implementation of electronic health records 2Health News:Chronic Pot Smoking Affects Brain Chemistry, Scans Show 2Health News:Joint Replacement Risks Rise at Less Experienced Hospitals 2Health News:Your attention please: 'Rewarding' objects can't be ignored 2Health News:Your attention please: 'Rewarding' objects can't be ignored 3Health News:For Gay Men, Serious Relationships Still Harbor Risks for HIV 2Health News:Mammary gland development of blueberry-fed lab animals studied 2
Standard knife with box, C profile...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
... Stages fit easily onto most microtomes. These ... only the AC supply and a trickle of ... immediately and can be maintained indefinitely. Stage ... can be set for different kinds of tissue. ...
ELISA kit for the quantitative determination of autoantibodies to glutamic acid decarboxylase (GAD65) in serum...
Medicine Products: